InsidersTradesSigma
申报总数
公司
▲ 买入（5 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
5
已披露卖出
0
T+90 胜率
33%
T+90 平均收益
+10.0%
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the complete record of transactions filed by Schimmel Paul, 董事. Officer active across 2 companies, notably aTYR PHARMA INC. In total, 7 filings have been published. Split: 5 buys · 0 sell. Total volume traded: €2.9m. History available since 18 May 2021. The latest transaction was filed on 8 October 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Schimmel Paul
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
682,001 股@ US$0.898100.0% 占其流量Common StockSEC:0001193125-25-236131:0
标准退出：2026年1月6日 (T+90)
41,052 股@ US$1.74172.6% 占其流量Common StockSEC:0000950170-24-086159:0
标准退出：2024年10月20日 (T+90)
200,000 股@ US$2.2516.3% 占其流量Common StockSEC:0001209191-23-028607:0
标准退出：2023年8月8日 (T+90)
6,000 股Common stockSEC:0001209191-23-026067:0
250,000 股@ US$8.0072.8% 占其流量Common StockSEC:0001209191-21-057339:0
标准退出：2021年12月19日 (T+90)
50,000 股@ US$3.986.9% 占其流量Common StockSEC:0001209191-21-034293:0
标准退出：2021年8月16日 (T+90)
11,925 股Common StockSEC:0001209191-16-094247:0
7 条申报中的 7 条
About Schimmel Paul
Paul Schimmel is a Board Member at aTYR Pharma Inc. He plays a key role in the governance of the company, contributing to strategic decision-making and overseeing operations. His experience in the pharmaceutical sector allows him to provide valuable insights to the board.
